Freenome (FRNM) – What Are Investment Firms Saying About This Stock?

Freenome (NASDAQ:FRNM) has been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $18.00.

FRNM has been the topic of a number of recent research reports. Weiss Ratings started coverage on Freenome in a research note on Monday, August 24th. They issued a “sell (d+)” rating on the stock. Leerink Partners assumed coverage on shares of Freenome in a report on Friday, August 14th. They issued an “outperform” rating and a $18.00 target price on the stock. BTIG Research reaffirmed a “buy” rating on shares of Freenome in a research note on Wednesday. Jefferies Financial Group initiated coverage on shares of Freenome in a report on Monday, August 17th. They set a “buy” rating and a $17.00 price target for the company. Finally, TD Cowen started coverage on shares of Freenome in a research report on Tuesday, August 18th. They issued a “buy” rating and a $17.00 price objective for the company.

Freenome Trading Down 1.9%

Shares of NASDAQ:FRNM traded down $0.20 during midday trading on Friday, hitting $10.41. 615,402 shares of the stock were exchanged, compared to its average volume of 795,181. The firm has a 50 day simple moving average of $13.97. Freenome has a twelve month low of $9.71 and a twelve month high of $17.50. The company has a market capitalization of $1.12 billion, a PE ratio of 20.41 and a beta of 0.60.

Freenome (NASDAQ:FRNM) last released its quarterly earnings results on Tuesday, November 10th. The company reported $1.10 EPS for the quarter. The business had revenue of $183.49 million during the quarter, compared to analyst estimates of $106.50 million.

About Freenome

Freenome is a biotechnology company developing blood-based tests intended to detect cancer at earlier stages. Its approach combines analysis of biological signals—including DNA and other biomarkers—with computational tools to identify patterns associated with disease. The company’s research has focused on multiomics screening, particularly for colorectal cancer. Freenome has evaluated its blood-based colorectal cancer test in clinical studies; the test is investigational, and its availability and regulatory status may vary.